 |
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2025, vol. 31, issue4
Subject Area: Medicine
-
DOI: 10.5272/jimab.2025314.6609
Published online: 12 November 2025
Review article
J of IMAB. 2025 Oct-Dec;31(4):6609-6614
SERUM AMYLOID A: A KEY MEDIATOR IN INFLAMMATION, METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE
Ademira Borisova
, Armine Grigoryan,
Department of Physiology and Pathophysiology, Faculty of Medicine, Medical University - Pleven, Bulgaria.
ABSTRACT:
Introduction: Serum Amyloid A (SAA) is a critical acute-phase protein involved in a range of physiological and pathological processes, including inflammation, lipid metabolism, and the regulation of the immune system. Recent investigations have underscored its significant role in various pathological conditions, such as cardiovascular diseases (CVD), type 2 diabetes mellitus, obesity-related disorders, and amyloidosis.
Objective: This review aims to elucidate the structural characteristics of serum amyloid A while assessing its pathological implications in metabolic and cardiovascular diseases. Additionally, we will evaluate its potential utility as a biomarker for disease diagnosis and management.
Methods: A systematic literature review was conducted utilizing reputable databases, including PubMed, Scopus, and Science Direct.
Results: The evidence presented indicates that SAA plays a significant role in the pathogenesis of atherosclerosis by disrupting high-density lipoprotein (HDL) metabolism, fostering oxidative stress, and enhancing vascular inflammation. In the contexts of obesity and type 2 diabetes mellitus, SAA produced by adipose tissue contributes to chronic inflammatory processes that promote insulin resistance and impair pancreatic β-cell function. Furthermore, persistently elevated levels of serum amyloid A in amyloidosis can lead to the misfolding and deposition of amyloid fibrils, which subsequently results in progressive organ dysfunction.
Conclusions: The diverse pathological effects of serum amyloid A underscore its importance as a key mediator in the pathogenesis of various diseases. Its potential as a biomarker for early diagnosis and monitoring warrants further exploration. Future research should prioritize elucidating the precise molecular mechanisms underlying serum amyloid A's actions and developing targeted strategies to mitigate its detrimental effects.
Keywords: serum amyloid A, cardiovascular diseases, type 2 diabetes mellitus, obesity-related conditions, amyloidosis,
- Download FULL TEXT /PDF 787 KB/
Please cite this article as: Borisova A, Grigoryan A. Serum Amyloid A: A key mediator in inflammation, metabolic disorders and cardiovascular disease. J of IMAB. 2025 Oct-Dec;31(4):6609-6614. [Crossref - 10.5272/jimab.2025314.6609]
Correspondence to: Ademira Miroslavova Borisova, Department of Physiology and Pathophysiology, Faculty of Medicine, Medical University-Pleven; 1, Sv. Kliment Ohridski Str., 5800 Pleven, Bulgaria; E-mail: ademira94@gmail.com
REFERENCES:
1. Ye RD, Sun L. Emerging functions of serum amyloid A in inflammation. J Leukoc Biol. 2015 Dec;98(6):923-929. [PubMed]
2. Zhang Y, Zhang J, Sheng H, Li H, Wang R. Acute phase reactant serum amyloid A in inflammation and other diseases. Adv Clin Chem. 2019;90:25-80. [PubMed]
3. Sack GH Jr. Serum amyloid A – a review. Mol Med. 2018 Aug 30;24(1):46. [PubMed]
4. den Hartigh LJ, May KS, Zhang XS, Chait A, Blaser MJ. Serum amyloid A and metabolic disease: evidence for a critical role in chronic inflammatory conditions. Front Cardiovasc Med. 2023 Jun 15;10:1197432. [PubMed ]
5. Rossmann C, Windpassinger C, Brunner D, Kovacevic A, Schweighofer N, Malli R, et al. Characterization of rat serum amyloid A4 (SAA4): a novel member of the SAA superfamily. Biochem Biophys Res Commun. 2014 August 8;450(4):1643-1649. [PubMed]
6. Sun L, Ye RD. Serum amyloid A1: structure, function and gene polymorphism. Gene. 2016 May 25;583(1):48-57. [PubMed]
7. Lu J, Yu Y, Zhu I, Cheng Y, Sun PD. Structural mechanism of serum amyloid A–mediated inflammatory amyloidosis. Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5189-5194. [PubMed]
8. Tannock LR, De Beer MC, Ji A, Shridas P, Noffsinger VP, den Hartigh LJ, et al. Serum amyloid A3 is a high density lipoprotein–associated acute phase protein. J Lipid Res. 2018 Feb;59(2):339-347. [PubMed]
9. Poitou C, Viguerie N, Cancello R, Coussieu C, Rouault C, Stich V, et al. Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia. 2005 Mar;48(3):519-528. [PubMed]
10. Vaktangova N, Moreira V, Castañón S, Aguilar R, Iglesias F. AA amyloidosis associated with morbid obesity (clinical case). Reumatol Clin. 2020 Nov 24;16(6):493-496. [PubMed]
11. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, Gong DW. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006 Jun;3(6):e287. [PubMed]
12. Liu T, Li M, Cui CY, Zhou J. Association between serum amyloid A levels and type 2 diabetes mellitus: a systematic review and meta-analysis. Endocrinol Metab (Seoul). 2023 Jun 7;38(3):315-327. [PubMed]
13. Ye X, Xue Y, Sha J, Li C, Zhen J. Serum amyloid A attenuates cellular insulin sensitivity by increasing JNK activity in 3T3 L1 adipocytes. J Endocrinol Invest. 2009 March 26;32(7):568-575. [PubMed]
14. Donath MY, Shoelson S. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011 Jan 14;11(2):98-107. [PubMed]
15. Faty A, Ferrй P, Commans S. The acute phase protein serum amyloid A induces lipolysis and inflammation in human adipocytes through distinct pathways. PLoS One. 2012 Apr 19;7(4):e34031. [PubMed]
16. Witting PK, Song C, Hsu K, Hua S, Parry SN, Aran R, et al. The acute phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high density lipoprotein. Free Radic Biol Med. 2011 Oct 1;51(7):1390-1398. [PubMed]
17. Gursky O. Structural basis for vital function and malfunction of serum amyloid A: an acute-phase protein that wears hydrophobicity on its sleeve. Curr Atheroscler Rep. 2020 September 24;22(11):69. [PubMed]
18. Mirioglu S, Uludag O, Hurdogan O, Kumru G, Berke I, Doumas SA, et al. AA amyloidosis: a contemporary view. Curr Rheumatol Rep. 2024 Apr 3;26(7):248-259. [PubMed]
19. lmoamly S, Obici L. Amyloidosis: Pathogenesis, Types, and Diagnosis. In: Paraproteinemia and Related Disorders. Ragab G, Quartuccio L, Goubran H, editors. Springer. 15 Nov. 2022. Chap 7:101-112. [Crossref]
20. Thorne J, Clark D, Geldenhuys L, More K, Vinson A, Tennankore K. Serum amyloid A protein–associated kidney disease: presentation, diagnosis, and management. Kidney Med. 2022 Aug;4(8):100504. [PubMed]
21. Pinney J, Lachmann HJ. Systemic AA amyloidosis. In: Harris JR, editor. Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease. Subcell Biochem. 2012;65:387-403. [Crossref]
22. Bloom MW, Gorevic PD. Cardiac amyloidosis. Ann Intern Med. 2023 Mar;176(3):ITC33-ITC48. [PubMed]
23. Pozzan M, Indennidate C, Varrà G, Sinagra G, Merlo M, Pagura L. Amyloidosis and amyloidogenesis: one name, many diseases. Heart Fail Clin. 2024 Jul;20(3):249-260. [Crossref]
24. Saremi S, Khajeh K. Amyloid fibril cytotoxicity and associated disorders. Prog Mol Biol Transl Sci. 2024;206:265-290. [Crossref]
25. Van der Hilst JCH, Frenkel J, Bijzet J, Weemaes CM, van der Meer JWM, Drenth JPH, et al. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP 1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford). 2008 Nov;47(11):1651-1654. [PubMed]
26. Shridas P, Tannock LR. Role of serum amyloid A in atherosclerosis. Curr Opin Lipidol. 2019 Aug;30(4):320-325. [PubMed]
27. Schoch L, Alcover A, Padrу T, Ben-Aicha S, Mendieta G, Badimon L, et al. Update of HDL in atherosclerotic cardiovascular disease. Clin Investig Arterioscler (Engl Ed). 2023 Nov-Dec;35(6):297-314. [PubMed]
28. Chiba T, Chang MY, Wang S, Wight TN, McMillen TS, Oram JF, et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol. 2011 Jun;31(6):1326-1332. [PubMed]
29. Kotani K, Asahara-Satoh N, Kato Y, Araki R, Himeno A, Yamakage H, et al. Remnant-like particle cholesterol and serum amyloid A-low-density lipoprotein levels in obese subjects with metabolic syndrome. J Clin Lipidol. 2011 Sep-Oct;5(5):395-400. [PubMed]
30. Kotani, K., Satoh, N., Yamada, T., & Gugliucci, A. The potential of serum amyloid A–LDL as a novel biomarker for cardiovascular disease risk. Clinical Lipidology, 5(4), 2010, 489–495. [Crossref]
31. Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2487-H2494. [PubMed]
32. Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep. 2009 Oct;14(5):187-196. [PubMed]
33. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009 Dec;54(23):2129-2138. [PubMed]
Received: 07 July 2025
Published online: 12 November 2025